What Is HPV? Understanding the Virus

Human papillomavirus — commonly known as HPV — is the most prevalent sexually transmitted infection on the planet. With more than 200 identified strains, HPV infects the epithelial cells of skin and mucous membranes and is transmitted primarily through intimate skin-to-skin contact. While most HPV infections are cleared naturally by the immune system within one to two years, persistent infection with certain high-risk strains can quietly lay the groundwork for a number of serious cancers over the course of a decade or more.

HPV is so common that the U.S. Centers for Disease Control and Prevention (CDC) estimates that nearly every sexually active person will contract at least one strain of HPV during their lifetime if they are unvaccinated. The sheer ubiquity of the virus, combined with its largely asymptomatic nature during early infection, makes it a uniquely dangerous public health challenge — and one that vaccination is specifically designed to address.

High-Risk vs. Low-Risk Strains

Not all HPV strains carry the same risk. Medical science classifies HPV strains into two broad categories:

• High-risk strains — Approximately 14 strains, including HPV-16 and HPV-18, are classified as high-risk oncogenic types because they can cause cancer. Together, HPV-16 and HPV-18 alone account for roughly 70% of all cervical cancers worldwide.
• Low-risk strains — Strains like HPV-6 and HPV-11 do not cause cancer but are responsible for genital warts (condylomata acuminata), which affect millions of people globally each year.

The biological mechanism of cancer development involves viral proteins — particularly E6 and E7 — that interfere with tumor suppressor proteins p53 and pRb respectively. When these critical cellular checkpoints are disabled, uncontrolled cell growth can occur, eventually leading to cancer over many years of persistent infection.

Cancers Caused by HPV

HPV is not just a cause of cervical cancer — it drives a spectrum of malignancies across different anatomical sites in both males and females. Understanding the full scope of HPV-associated cancers is essential context for appreciating why vaccination programs are a major cancer prevention strategy.

According to the CDC, HPV is responsible for approximately 45,000 new cancer cases in the United States each year. Globally, HPV-attributable cancers account for roughly 5% of all cancers worldwide — a staggering figure given that this is almost entirely preventable with vaccination.

Cervical Cancer

Cervical cancer remains the most directly and thoroughly studied HPV-associated malignancy. Nearly 99% of all cervical cancers are attributable to HPV infection, making it the one cancer most fundamentally transformed by vaccination. Globally, cervical cancer is the fourth most common cancer in women, with approximately 604,000 new cases and 342,000 deaths recorded in 2020 according to World Health Organization data. The vast majority of these deaths occur in low- and middle-income countries where vaccine access and screening programs remain limited.

Oropharyngeal Cancer

HPV-associated oropharyngeal cancer — cancers of the back of the throat, base of the tongue, and tonsils — has been rising sharply in incidence, particularly among men in developed nations. HPV-16 is responsible for the majority of these cases. Oropharyngeal cancer is now the most common HPV-associated cancer in the United States, surpassing cervical cancer in absolute numbers, and projections suggest this trend will continue without significantly expanded vaccination coverage.

Other HPV-Related Cancers

• Anal cancer — HPV is implicated in up to 91% of anal cancers; risk is elevated among men who have sex with men (MSM) and immunocompromised individuals.
• Vulvar and vaginal cancer — Approximately 75% of vaginal cancers and 69% of vulvar cancers are attributable to HPV.
• Penile cancer — Around 63% of penile cancers are HPV-related, with HPV-16 being the dominant strain.
• Recurrent respiratory papillomatosis — Though not a cancer, this rare but debilitating condition caused by HPV-6 and HPV-11 can lead to life-threatening airway obstruction in children born to infected mothers.

HPV Vaccines: Types and Availability

Since the first HPV vaccine was approved in 2006, the technology has evolved considerably. Currently, three vaccines have been developed, though availability varies by country.

Gardasil 9: The Gold Standard

Gardasil 9, the nine-valent vaccine approved by the U.S. Food and Drug Administration (FDA) in 2014, is now the primary HPV vaccine used in North America, Europe, Australia, and an increasing number of countries worldwide. By targeting nine strains — including the two that cause 90% of genital warts and seven high-risk oncogenic types — Gardasil 9 is estimated to prevent approximately 90% of HPV-attributable cancers.

All three vaccines are recombinant vaccines, meaning they contain virus-like particles (VLPs) — protein shells that mimic the outer coat of the HPV virus but contain no viral DNA. This means the vaccine cannot cause HPV infection; it simply trains the immune system to recognize and mount a defense against real HPV viral proteins if encountered in the future.

Who Should Be Vaccinated?

Understanding who benefits from HPV vaccination — and when — is central to making informed health decisions. Global health authorities, including the WHO, CDC, and European Centre for Disease Prevention and Control (ECDC), have issued consistent and overlapping guidance on vaccination schedules.

Adolescents: The Primary Target Group

The HPV vaccine is most effective when given before any potential exposure to the virus — that is, before sexual activity begins. For this reason, the primary target group across most national programs is adolescents aged 9 to 12 years old, typically boys and girls alike. At this age, the immune response to the vaccine is also notably stronger, meaning that two doses, rather than three, provide complete protection.

Catch-Up Vaccination: Ages 13–26

For individuals who were not vaccinated as adolescents, catch-up vaccination is strongly recommended up to age 26. Even if a person has been exposed to one HPV strain, vaccination still provides protection against the other strains in the vaccine. The CDC’s Advisory Committee on Immunization Practices (ACIP) recommends catch-up vaccination for all people through age 26 who were not adequately vaccinated.

Adults Ages 27–45: Shared Decision-Making

For adults aged 27 to 45, the recommendation becomes more nuanced. The FDA has approved Gardasil 9 for this age group, but because many adults in this range have already been exposed to HPV strains covered by the vaccine, the public health benefit at a population level is more limited. The CDC recommends that adults in this age group speak with their healthcare provider about whether vaccination is right for them — a process known as shared clinical decision-making.

Immunocompromised Individuals

People who are immunocompromised — including those living with HIV — are at significantly higher risk for persistent HPV infection and HPV-related cancers. Three doses are recommended for this population regardless of the age at which vaccination begins, as the immune response may be diminished.

Dosing Schedule

The number of doses required depends on the age at which the vaccination series is initiated. The schedule recommended by the CDC and WHO is as follows:

Efficacy and Real-World Effectiveness

The clinical trial data underpinning HPV vaccine approval is among the most rigorous ever assembled for a preventive medicine product. And the real-world evidence since widespread vaccination began in 2006 has been, by any scientific standard, remarkable.

Clinical Trial Data

Clinical trials for Gardasil 9 demonstrated close to 100% efficacy against cervical, vulvar, and vaginal lesions caused by the nine HPV strains in the vaccine, in individuals who had not previously been infected with those strains. The original four-valent Gardasil showed 98% efficacy against HPV-16 and HPV-18 related cervical precancers in clinical trials.

Population-Level Impact

Countries that implemented national HPV vaccination programs early — particularly Australia, the United Kingdom, and the Nordic nations — have provided compelling population-level evidence of the vaccine’s transformative impact:

• Australia, which launched a national school-based program in 2007, has documented reductions of over 90% in genital wart diagnoses among young women and men. Australia is on track to become the first country to eliminate cervical cancer as a public health problem — defined as fewer than 4 cases per 100,000 women per year — largely due to vaccination combined with screening.
• Scotland reported that girls vaccinated at age 12–13 with the bivalent Cervarix vaccine showed a 89% reduction in cervical cancer incidence compared to unvaccinated women, according to a landmark study published in The Lancet in 2021.
• United States data from the CDC shows that HPV infections from vaccine-targeted strains dropped by 88% among teenage girls and 81% among women aged 20–24 in the decade following vaccine introduction.
• Sweden published research showing that girls vaccinated before age 17 had a 63% lower rate of cervical cancer than unvaccinated individuals — and those vaccinated before age 17 showed an even greater reduction of 88%.

Safety Profile and Side Effects

With over one billion doses administered globally across nearly two decades, the HPV vaccine has one of the most thoroughly studied safety profiles of any vaccine in medical history. Major regulatory agencies — including the FDA, the European Medicines Agency (EMA), and the WHO’s Global Advisory Committee on Vaccine Safety (GACVS) — have repeatedly reviewed the accumulated safety data and consistently affirmed the vaccine’s safety.

Common, Mild Side Effects

Like all vaccines, HPV vaccines can cause mild and temporary side effects that reflect a normal immune response:

• Injection site reactions: pain, redness, and swelling (the most common side effects, reported in up to 90% of recipients)
• Mild to moderate fever
• Headache and fatigue
• Nausea and dizziness, particularly in adolescents
• Syncope (fainting) — common in adolescents immediately after any injection; patients are typically observed for 15 minutes post-vaccination

Rare Adverse Events

Serious adverse events following HPV vaccination are rare. Post-licensure surveillance systems, including VAERS in the United States and Yellow Card in the UK, have detected no new safety signals beyond what was observed in clinical trials. Anaphylaxis — a severe allergic reaction — occurs at a rate of approximately 1.7 per million doses, consistent with other vaccines.

Contraindications

The HPV vaccine should not be given to individuals with a known severe allergic reaction (anaphylaxis) to any component of the vaccine or to a previous dose. The vaccine is also not recommended during pregnancy, although no evidence of harm has been found in cases where pregnant individuals inadvertently received it. Vaccination can resume after delivery.

Gender-Inclusive Vaccination: Protecting Everyone

A critical evolution in HPV vaccination policy over the past decade has been the expansion of programs to include all genders. Early programs in many countries initially targeted only girls, reasoning that vaccination of females would reduce transmission broadly. However, this approach was ultimately recognized as both scientifically and ethically insufficient.

Why Males Need the Vaccine Too

Males are not merely vectors of HPV to female partners — they are themselves at significant risk of HPV-associated disease. HPV causes virtually all anal cancers, a majority of penile cancers, and increasingly, a large proportion of oropharyngeal cancers — many of which affect men. Furthermore, HPV-6 and HPV-11 cause genital warts in both sexes. Vaccinating males protects them directly, while also contributing to herd immunity that protects unvaccinated individuals in the broader population.

Australia included boys in its national program in 2013. The United States expanded its routine recommendation to include males in 2011. The WHO now recommends gender-neutral vaccination programs wherever feasible, particularly given the rising burden of HPV-associated oropharyngeal cancer in men.

Vaccination and the LGBTQ+ Community

Men who have sex with men (MSM) and transgender women face disproportionately higher rates of HPV-associated anal cancer and genital warts. The CDC specifically highlights MSM as a priority group for catch-up vaccination through age 26, with shared decision-making up to age 45 for those not previously vaccinated. Ensuring equitable access to vaccination for LGBTQ+ individuals is a recognized component of comprehensive sexual health care.

Global Disparities and the Path to Elimination

Perhaps the most troubling dimension of the HPV story is the stark geographical inequality in vaccination access. While countries like Australia, Canada, the United Kingdom, and the United States have vaccination rates above 70–80% in eligible populations and are witnessing dramatic declines in HPV-related disease, the burden continues to fall overwhelmingly on low- and middle-income countries (LMICs).

Approximately 85% of global cervical cancer deaths occur in LMICs, primarily in sub-Saharan Africa, South and Southeast Asia, and Latin America. These are regions where girls are least likely to be vaccinated, least likely to be screened, and least likely to access treatment if cancer is diagnosed.

WHO’s 90-70-90 Strategy

In 2020, the WHO launched a global strategy to accelerate the elimination of cervical cancer, with specific targets to be reached by 2030:

1. 90% of girls fully vaccinated with the HPV vaccine by age 15
2. 70% of women screened with a high-performance test by age 35 and again by age 45
3. 90% of women identified with cervical disease receiving treatment

Reaching these targets would prevent 74 million new cervical cancer cases and save 62 million lives over the following 100 years, according to WHO modeling. The challenge is immense, but the roadmap is clear. GAVI, the Vaccine Alliance — supported by funding from the Gates Foundation and donor nations — has made HPV vaccine access in LMICs a priority, with the price per dose in eligible countries reduced dramatically through volume-based negotiations.

HPV Vaccination and Cervical Cancer Screening

It is critically important to understand that HPV vaccination and cervical cancer screening are complementary, not interchangeable. Vaccination prevents future infection with targeted HPV strains; screening detects existing precancerous or cancerous changes that may have resulted from past infection — including infections with HPV types not covered by the vaccine.

Continued Screening After Vaccination

All vaccinated individuals with a cervix should continue to follow recommended cervical cancer screening guidelines. In the United States, the ACOG (American College of Obstetricians and Gynecologists) recommends:

• First cervical cancer screening (Pap test) at age 21, regardless of vaccination status
• Pap test every 3 years from ages 21–29
• From age 30–65: Pap test every 3 years, or HPV test every 5 years, or co-testing (Pap + HPV) every 5 years
• Vaccinated individuals should follow the same screening intervals as unvaccinated individuals — some guidelines are beginning to explore whether vaccinated cohorts may benefit from modified screening intervals in the future

HPV Testing as a Primary Screening Tool

Primary HPV testing — using high-sensitivity molecular assays that detect HPV DNA directly — is increasingly replacing or supplementing traditional cytology-based Pap smears as a first-line screening approach. HPV testing is more sensitive than cytology for detecting high-grade cervical precancers and is now recommended as a preferred screening method in several countries, including the United States, Australia, and the Netherlands.

Common Myths and Scientific Facts

Despite the overwhelming evidence supporting HPV vaccination, misconceptions persist — and they have real consequences for public health. Addressing these myths directly is essential for informed decision-making.

Myth: The vaccine encourages sexual promiscuity

Multiple large-scale studies have specifically investigated this concern. A 2012 study published in Pediatrics and subsequent research found no evidence that HPV vaccination is associated with increased sexual activity, earlier sexual debut, or changes in contraceptive behavior. The vaccine prevents cancer — its mechanism has no relationship to sexual decision-making.

Myth: The vaccine is only for girls

As discussed above, this is scientifically outdated. All major health authorities now recommend HPV vaccination for all genders. HPV causes significant cancer burden in males, and gender-neutral vaccination is demonstrably more effective at population-level protection.

Myth: If you’ve already had HPV, the vaccine is useless

Because the vaccine covers multiple HPV strains, individuals previously exposed to one strain can still benefit from protection against the others. Vaccination is recommended even for sexually active individuals who may have been exposed to HPV, unless they are known to have been infected with all strains in the vaccine — a practically impossible scenario to verify.

Myth: The vaccine hasn’t been tested enough to be safe

HPV vaccines underwent some of the most extensive pre-licensure clinical trials of any vaccine, involving tens of thousands of participants across multiple countries over several years. Post-licensure surveillance covering over one billion doses over nearly 20 years has not uncovered any unexpected serious safety signals. This safety record is exemplary by any standard of comparison.

Future Directions in HPV Vaccination

The science of HPV prevention continues to evolve. Several emerging developments promise to further expand the reach and impact of vaccination programs in the coming decade.

Single-Dose Regimens

One of the most significant recent developments is mounting evidence that a single dose of HPV vaccine may provide robust, durable protection. A landmark randomized controlled trial in Kenya — the KEN SHE study — published in The Lancet in 2022 found that a single dose of Gardasil 9 or Cervarix provided approximately 97.5% efficacy against HPV-16 and HPV-18 infection over 18 months. The WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) reviewed this evidence in 2022 and updated its recommendation to support single-dose schedules for girls aged 9–14 and young women aged 15–20, which could dramatically simplify global rollout and improve coverage in resource-limited settings.

Therapeutic Vaccines

Current HPV vaccines are prophylactic — they prevent infection but do not treat existing HPV infections or HPV-associated cancers. Researchers are actively developing therapeutic HPV vaccines designed to stimulate a targeted immune response against cells already infected with HPV, potentially treating precancerous lesions or even established cancers. Several candidates are in Phase II and Phase III clinical trials, with promising early results.

Next-Generation Nonavalent and Broader Vaccines

While Gardasil 9 already covers the vast majority of oncogenic HPV strains, research is ongoing into even broader vaccines that would cover additional rare high-risk strains, potentially pushing prevention rates even closer to 100% for HPV-attributable cancers.

Integration with mRNA Technology

The success of mRNA vaccine platforms during the COVID-19 pandemic has accelerated interest in applying this technology to HPV vaccines. mRNA-based HPV vaccines in development offer the possibility of even greater flexibility in formulation, faster development timelines, and potentially stronger immune responses.

Talking to Your Healthcare Provider

Deciding on vaccination for yourself or your child can feel overwhelming given the volume of information available — and the volume of misinformation that competes with it. The most reliable starting point is always a conversation with a trusted healthcare provider who can assess individual health history, current guidelines applicable in your country, and any specific circumstances that might affect recommendations.

When speaking with a provider, consider asking:

• Which HPV vaccine is recommended and available in my region?
• What is the recommended schedule given my age and vaccination history?
• Are there any contraindications I should be aware of based on my health history?
• Does HPV vaccination affect the cervical cancer screening schedule I should follow?
• Is catch-up vaccination appropriate for me as an adult?

It is also worth noting that in many countries, HPV vaccines are available through school-based immunization programs, community health clinics, family planning services, and general practitioners. Cost is a common barrier to vaccination in some settings — many national health systems cover HPV vaccination without charge for target age groups, and financial assistance programs may be available for those who face cost barriers outside covered ages.

Conclusion: A Generational Opportunity

The HPV vaccine represents one of the most extraordinary achievements in preventive medicine. It is not merely a vaccine against a virus — it is a vaccine against cancer. For the first time in human history, we have a tool that can prevent hundreds of thousands of cancer deaths annually through a safe, well-tested, and widely available immunization.

The science is settled. The data from nearly two decades of real-world use is unambiguous. In countries with high vaccination coverage, cervical cancer is already becoming rare among vaccinated generations. Australia is close to eliminating it entirely. These outcomes were once theoretical — now they are documented reality.

The remaining challenge is not scientific but logistical, political, and social: ensuring that every eligible person, regardless of geography, gender, socioeconomic status, or sexual orientation, has access to this protection. Bridging the gap between high-income countries where vaccination is routine and low-income countries where the cancer burden is highest is the defining public health challenge for HPV in the decade ahead.

For individuals and families reading this today, the message is clear: if you or your child is within the recommended age range, HPV vaccination is one of the most meaningful preventive health decisions you can make. Cancer prevention does not get more direct — or more proven — than this.